Close Menu

NEW YORK – Omniome announced Thursday that it has raised $60 million in Series C financing, led by Madrone Capital Partners.

The San Diego-based firm said in a statement that it would use the funds to "accelerate late-stage product development and launch planning," continue optimizing its "scar-free" sequencing biochemistry, and further develop its instrument. It will also expand its workforce, especially in manufacturing, engineering, development, customer support, and commercial operations.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

A German shepherd called Nala has had her genome sequenced.

A coronavirus serology test garners Emergency Use Authorization from the US Food and Drug Administration, but the Los Angeles Times asks: how will tests like that be used?

Certain gene variants in conjunction with a healthy lifestyle may keep brains young, according to New Scientist.

In Science this week: increased CD8 T cell density and increased IFN-gamma response may indicate metastatic prostate cancer patients who will respond to immune checkpoint blockade therapy.

May
06
Sponsored by
Isoplexis

This webinar will discuss the application of single-cell proteomics and immune-imaging in adoptive cell therapy (ACT) for cancer.